GlassScriptPhysician profile
Sarah Gregory
NPI 1881060002
$8,975.80
in general payments reported to CMS, 2019-2025
31 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,509 · 2022: $1,251 · 2023: $4,053 · 2024: $922 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,058 · Travel and Lodging: $2,079 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.19 |
| Travel and Lodging | $2,079.30 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,762.85 | 2021-2025 | Vercise, Watchman Flx |
| Medtronic, INC. | $1,588.08 | 2021-2024 | Venaseal, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $747.56 | 2021-2025 | Lifevest |
| Amgen INC. | $746.01 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $618.92 | 2021-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $574.19 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $515.48 | 2022-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $509.54 | 2021-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.33 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $225.77 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $221.80 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $220.69 | 2021-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $190.42 | 2024-2025 | |
| Novo Nordisk INC | $166.94 | 2025 | Ozempic |
| Lantheus Medical Imaging, INC. | $98.01 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $91.69 | 2025 | |
| Esperion Therapeutics, INC. | $83.74 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $51.38 | 2025 | Assure Wcd |
| Baxter Healthcare | $31.50 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $23.81 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.39 | 2022 | |
| Grt US Holding, INC. | $22.85 | 2022 | |
| Bard Peripheral Vascular, INC. | $22.24 | 2023 | Venclose Maven Catheter |
| Cvrx, INC. | $20.80 | 2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $20.77 | 2023 | Arcalyst |
| Angiodynamics, INC. | $20.47 | 2022 | |
| Tersera Therapeutics LLC | $20.41 | 2022 | |
| Philips North America LLC | $18.16 | 2022 | |
| Cardiovascular Systems INC. | $14.70 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.66 | 2022 | |
| Cashflow Solutions, LLC | $13.64 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.